Funding for this research was provided by:
3D Medicines Co., Ltd, China
Received: 18 May 2021
Accepted: 21 May 2021
First Online: 21 June 2021
: The study was approved at each site by the local independent ethics committee. All enrolled patients provided signed, informed consent for participation.
: Not applicable.
: SX, HL, JG, and DL are employees of and own stock in 3D Medicines Co., Ltd. JG and DL have leadership roles at 3D Medicines Co., Ltd. LS has received research funding from 3D Medicines Co., Ltd. XT is an employee of Alphamab Co., Ltd, where he has a leadership role and owns stock. The other authors declare no conflicts of interest.